Discovery of HDAC inhibitors with potent activity against multiple malaria parasite life cycle stages Dedicated to Prof. Dr. Alan R. Katritzky, in memoriam.

European Journal of Medicinal Chemistry

Volumn 82, Issue , 2014, Pages 204-213

  Hansen, Finn K ^a   Sumanadasa, Subathdrage D M ^b   Stenzel, Katharina ^a   Duffy, Sandra ^b   Meister, Stephan ^c   Marek, Linda ^a   Schmetter, Rebekka ^a   Kuna, Krystina ^a   Hamacher, Alexandra ^a   Mordmüller, Benjamin ^d,e   Kassack, Matthias U ^a   Winzeler, Elizabeth A ^c   Avery, Vicky M ^b   Andrews, Katherine T ^b   Kurz, Thomas ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b GRIFFITH UNIVERSITY   (Australia)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d UNIVERSITY OF TÜBINGEN   (Germany)

^e ALBERT SCHWEITZER HOSPITAL   (Gabon)

Author keywords

Asexual blood stages; Gametocyte stages; Histone deacetylase inhibitor; Liver stages; Malaria

Indexed keywords

2 FLUORO N [[6 (HYDROXYAMINO) 6 OXOHEXYL]OXY]BENZAMIDE; 4 (HEXYLOXY) N [[6 (HYDROXYAMINO) 6 OXOHEXYL]OXY]BENZAMIDE; 4 (TERT BUTYL) N [[6 (HYDROXYAMINO) 6 OXOHEXYL]OXY]BENZAMIDE; 4 BUTOXY N [[6 (HYDROXYAMINO) 6 OXOHEXYL]OXY]BENZAMIDE; 4 BUTYL N [[6 (HYDROXYAMINO) 6 OXOHEXYL]OXY]BENZAMIDE; 4 ETHOXY N [[6 (HYDROXYAMINO) 6 OXOHEXYL]OXY]BENZAMIDE; ANTIMALARIAL AGENT; ARTESUNATE; ATOVAQUONE; CHLOROQUINE; HISTONE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE INHIBITOR; LMK 235; N [[6 (HYDROXYAMINO) 6 OXOHEXYL]OXY] 2 PROPOXYBENZAMIDE; N [[6 (HYDROXYAMINO) 6 OXOHEXYL]OXY] 3 PROPOXYBENZAMIDE; N [[6 (HYDROXYAMINO) 6 OXOHEXYL]OXY] 4 (PENTYLOXY)BENZAMIDE; N [[6 (HYDROXYAMINO) 6 OXOHEXYL]OXY] 4 ISOPROPOXYBENZAMIDE; N [[6 (HYDROXYAMINO) 6 OXOHEXYL]OXY] 4 PROPOXYBENZAMIDE; N [[6 (HYDROXYAMINO) 6 OXOHEXYL]OXY]FURAN 2 CARBOXAMIDE; PYRONARIDINE; RECOMBINANT ENZYME; SB 939; TRICHOSTATIN A; UNCLASSIFIED DRUG; VORINOSTAT; WR 301801; HDAC4 PROTEIN, HUMAN; HDAC5 PROTEIN, HUMAN; HISTONE DEACETYLASE; REPRESSOR PROTEIN;

ANTIMALARIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; ERYTHROCYTE; GAMETOCYTE; HEPG2 CELL LINE; HISTONE ACETYLATION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MALARIA FALCIPARUM; MAMMAL CELL; NONHUMAN; PLASMODIUM (LIFE CYCLE STAGE); PLASMODIUM BERGHEI; SOLID; SPOROZOITE; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG DEVELOPMENT; DRUG EFFECTS; DRUG SENSITIVITY; GROWTH, DEVELOPMENT AND AGING; METABOLISM; PLASMODIUM FALCIPARUM; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ANTIMALARIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DISCOVERY; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; MOLECULAR STRUCTURE; PARASITIC SENSITIVITY TESTS; PLASMODIUM FALCIPARUM; REPRESSOR PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84902147732     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2014.05.050     Document Type: Article

References (44)

1. World Health Organization World Malaria Report 2011 2012 WHO Press Geneva
2. C.J. Murray, L.C. Rosenfeld, S.S. Lim, K.G. Andrews, K.J. Foreman, D. Haring, N. Fullman, M. Naghavi, R. Lozano, and A.D. Lopez Global malaria mortality between 1980 and 2010: a systematic analysis Lancet 379 2012 413 431
3. S. Abdulla, N. Salim, F. Machera, R. Kamata, O. Juma, M. Shomari, S. Kubhoja, A. Mohammed, G. Mwangoka, T. Aebi, H. Mshinda, D. Schellenberg, T. Carter, T. Villafana, M.-C. Dubois, A. Leach, M. Lievens, J. Vekemans, J. Cohen, W.R. Ballou, and M. Tanner Randomized, controlled trial of the long term safety, immunogenicity and efficacy of RTS,S/AS02(D) malaria vaccine in infants living in a malaria-endemic region Malar. J. 12 2013 11
4. S.T. Agnandji, B. Lell, S.S. Soulanoudjingar, J.F. Fernandes, B.P. Abossolo, C. Conzelmann, B.G. Methogo, Y. Doucka, A. Flamen, B. Mordmüller, S. Issifou, P.G. Kremsner, J. Sacarlal, P. Aide, M. Lanaspa, J.J. Aponte, A. Nhamuave, D. Quelhas, Q. Bassat, S. Mandjate, E. Macete, P. Alonso, S. Abdulla, N. Salim, O. Juma, M. Shomari, K. Shubis, F. Machera, A.S. Hamad, R. Minja, A. Mtoro, A. Sykes, S. Ahmed, A.M. Urassa, A.M. Ali, G. Mwangoka, M. Tanner, H. Tinto, U. D'Alessandro, H. Sorgho, I. Valea, M.C. Tahita, W. Kabore, S. Ouedraogo, Y. Sandrine, R.T. Guiguemde, J.B. Ouedraogo, M.J. Hamel, S. Kariuki, C. Odero, M. Oneko, K. Otieno, N. Awino, J. Omoto, J. Williamson, V. Muturi-Kioi, K.F. Laserson, L. Slutsker, W. Otieno, L. Otieno, O. Nekoye, S. Gondi, A. Otieno, B. Ogutu, R. Wasuna, V. Owira, D. Jones, A.A. Onyango, P. Njuguna, R. Chilengi, P. Akoo, C. Kerubo, J. Gitaka, C. Maingi, T. Lang, A. Olotu, B. Tsofa, P. Bejon, N. Peshu, K. Marsh, S. Owusu-Agyei, K.P. Asante, K. Osei-Kwakye, O. Boahen, S. Ayamba, K. Kayan, R. Owusu-Ofori, D. Dosoo, I. Asante, G. Adjei, D. Chandramohan, B. Greenwood, J. Lusingu, S. Gesase, A. Malabeja, O. Abdul, H. Kilavo, C. Mahende, E. Liheluka, M. Lemnge, T. Theander, C. Drakeley, D. Ansong, T. Agbenyega, S. Adjei, H.O. Boateng, T. Rettig, J. Bawa, J. Sylverken, D. Sambian, A. Agyekum, L. Owusu, F. Martinson, I. Hoffman, T. Mvalo, P. Kamthunzi, R. Nkomo, A. Msika, A. Jumbe, N. Chome, D. Nyakuipa, J. Chintedza, W.R. Ballou, M. Bruls, J. Cohen, Y. Guerra, E. Jongert, D. Lapierre, A. Leach, M. Lievens, O. Ofori-Anyinam, J. Vekemans, T. Carter, D. Leboulleux, C. Loucq, A. Radford, B. Savarese, D. Schellenberg, M. Sillman, and P. Vansadia First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children N. Engl. J. Med. 365 2011 1863 1875
5. S. Turschner, and T. Efferth Drug resistance in Plasmodium: natural products in the fight against malaria Mini Rev. Med. Chem. 9 2009 206 214
6. A.M. Dondorp, F. Nosten, P. Yi, D. Das, A.P. Phyo, J. Tarning, K.M. Lwin, F. Ariey, W. Hanpithakpong, S.J. Lee, P. Ringwald, K. Silamut, M. Imwong, K. Chotivanich, P. Lim, T. Herdman, S.S. An, S. Yeung, P. Singhasivanon, N.P. Day, N. Lindegardh, D. Socheat, and N.J. White Artemisinin resistance in Plasmodium falciparum malaria N. Engl. J. Med. 361 2009 455 467
7. A.M. Dondorp, S. Yeung, L. White, C. Nguon, N.P. Day, D. Socheat, and L. von Seidlein Artemisinin resistance: current status and scenarios for containment Nat. Rev. Microbiol. 8 2010 272 280
8. The maIERA Consultative Group on Drugs A research agenda for malaria eradication: drugs PLoS Med. 8 2011 e1000402
9. J.N. Burrows Antimalarial drug discovery: where next? Future Med. Chem. 4 2012 2233 2235
10. T. Rodrigues, M. Prudêncio, R. Moreira, M.M. Mota, and F. Lopes Targeting the liver stage of malaria parasites: a yet unmet goal J. Med. Chem. 55 2012 995 1012
11. O. Dechy-Cabaret, and F. Benoit-Vical Effects of antimalarial molecules on the gametocyte stage of Plasmodium falciparum: the debate J. Med. Chem. 55 2012 10328 10344
12. L. Lucantoni, and V. Avery Whole-cell in vitro screening for gametocytocidal compounds Future Med. Chem. 4 2012 2337 2360
13. K.T. Andrews, T.N. Tran, and D.P. Fairlie Towards histone deacetylase inhibitors as new antimalarial drugs Curr. Pharm. Des. 18 2012 3467 3479
14. K.T. Andrews, T.N. Tran, N.C. Wheatley, and D.P. Fairlie Targeting histone deacetylase inhibitors for anti-malarial therapy Curr. Top. Med. Chem. 9 2009 292 308
15. M. Biel, V. Wascholowski, and A. Giannis Epigenetics - an epicenter of gene regulation: histones and histone-modifying enzymes Angew. Chem. Int. Ed. 44 2005 3186 3216 (Pubitemid 40778337)
16. P. Bertrand Inside HDAC with HDAC inhibitors Eur. J. Med. Chem. 45 2010 2095 2116
17. O. Witt, H.E. Deubzer, T. Milde, and I. Oehme HDAC family: what are the cancer relevant targets? Cancer Lett. 277 2009 8 21
18. W.S. Xu, R.B. Parmigiani, and P.A. Marks Histone deacetylase inhibitors: molecular mechanisms of action Oncogene 26 2007 5541 5552 (Pubitemid 47255934)
19. X.-J. Yang, and E. Seto HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention Oncogene 26 2007 5310 5318 (Pubitemid 47255917)
20. S. Balasubramanian, E. Verner, and J.J. Buggy Isoform-specific histone deacetylase inhibitors: the next step? Cancer Lett. 280 2009 211 221
21. O. Khan, and N.B. La Thangue HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications Immunol. Cell. Biol. 90 2012 85 94
22. P. Horrocks, E. Wong, K. Russell, and R.D. Emes Control of gene expression in Plasmodium falciparum - ten years on Mol. Biochem. Parasitol. 164 2009 9 25
23. V. Patel, R. Mazitschek, B. Coleman, C. Nguyen, S. Urgaonkar, J. Cortese, R.H. Barker, E. Greenberg, W. Tang, J.E. Bradner, S.L. Schreiber, M.T. Duraisingh, D.F. Wirth, and J. Clardy Identification and characterization of small molecule inhibitors of a class I histone deacetylase from Plasmodium falciparum J. Med. Chem. 52 2009 2185 2187
24. G. Hu, A. Cabrera, M. Kono, S. Mok, B.K. Chaal, S. Haase, K. Engelberg, S. Cheemadan, T. Spielmann, P.R. Preiser, T.-W. Gilberger, and Z. Bozdech Transcriptional profiling of growth perturbations of the human malaria parasite Plasmodium falciparum Nat. Biotechnol. 28 2010 91 98
25. K.T. Andrews, A.P. Gupta, T.N. Tran, D.P. Fairlie, and G.N. Gobert Comparative gene expression profiling of P. falciparum malaria parasites exposed to three different histone deacetylase inhibitors PLoS ONE 7 2012 e31847
26. B.K. Chaal, A.P. Gupta, B.D. Wastuwidyaningtyas, Y.-H. Luah, and Z. Bozdech Histone deacetylases play a major role in the transcriptional regulation of the Plasmodium falciparum life cycle PLoS Pathog. 6 2010 e1000737
27. S. Mok, M. Imwong, M.J. Mackinnon, J. Sim, R. Ramadoss, P. Yi, M. Mayxay, K. Chotivanich, K.-Y. Liong, B. Russell, D. Socheat, P.N. Newton, N.P.J. Day, N.J. White, P.R. Preiser, F. Nosten, A.M. Dondorp, and Z. Bozdech Artemisinin resistance in Plasmodium falciparum is associated with an altered temporal pattern of transcription BMC Gen. 12 2011 391
28. G.S. Dow, Y. Chen, K.T. Andrews, D. Caridha, L. Gerena, M. Gettayacamin, J. Johnson, Q. Li, V. Melendez, N. Obaldia, T.N. Tran, and A.P. Kozikowski Antimalarial activity of phenylthiazolyl-bearing hydroxamate-based histone deacetylase inhibitors Antimicrob. Ag. Chemother. 52 2008 3467 3477
29. S.D.M. Sumanadasa, C.D. Goodman, A.J. Lucke, T. Skinner-Adams, I. Sahama, A. Haque, T.A. Do, G.I. McFadden, D.P. Fairlie, and K.T. Andrews Antimalarial activity of the anticancer histone deacetylase inhibitor SB939 Antimicrob. Ag. Chemother. 56 2012 3849 3856
30. L. Marek, A. Hamacher, F.K. Hansen, K. Kuna, H. Gohlke, M.U. Kassack, and T. Kurz Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells J. Med. Chem. 56 2013 427 436
31. V. Duléry, O. Renaudet, and P. Dumy Ethoxyethylidene protecting group prevents N-overacylation in aminooxy peptide synthesis Tetrahedron 63 2007 11952 11958 (Pubitemid 47575619)
32. S. Foillard, M.O. Rasmussen, J. Razkin, D. Boturyn, and P. Dumy 1-Ethoxyethylidene, a new group for the stepwise SPPS of aminooxyacetic acid containing peptides J. Org. Chem. 73 2008 983 991 (Pubitemid 351198742)
33. B. Draghici, F.K. Hansen, A.-M. Buciumas, B.E.-D.M. El-Gendy, E. Todadze, and A.R. Katritzky Efficient microwave-assisted synthesis of aminoxy acid conjugates RSC Adv. 1 2011 602 606
34. C. Jiménez-Castells, B.G. de la Torre, R. Gutiérrez Gallego, and D. Andreu Optimized synthesis of aminooxy-peptides as glycoprobe precursors for surface-based sugar-protein interaction studies Bioorg. Med. Chem. Lett. 17 2007 5155 5158 (Pubitemid 47259648)
35. C.A. Lipinski, F. Lombardo, B.W. Dominy, and P.J. Feeney Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug. Deliv. Rev. 46 2001 3 26 (Pubitemid 33653411)
36. F.K. Hansen, T.S. Skinner-Adams, S. Duffy, L. Marek, S.D.M. Sumanadasa, K. Kuna, J. Held, V.M. Avery, K.T. Andrews, and T. Kurz Synthesis, antimalarial properties and SAR studies of alkoxyurea-based HDAC inhibitors ChemMedChem 9 2014 665 670
37. B. Jones The halogenation of phenolic ethers and anilides. Part XIV. m-substituted phenyl ethers J. Chem. Soc. 1943 430 432
38. R.E. Desjardins, C.J. Canfield, J.D. Haynes, and J.D. Chulay Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique Antimicrob. Ag. Chemother. 16 1979 710 718 (Pubitemid 10082023)
39. W. Huber, and J.C. Koella A comparison of three methods of estimating EC50 in studies of drug resistance of malaria parasites Acta Trop. 55 1993 257 261
40. D.L. Baldi, K.T. Andrews, R.F. Waller, D.S. Roos, R.F. Howard, B.S. Crabb, and A.F. Cowman RAP1 controls rhoptry targeting of RAP2 in the malaria parasite Plasmodium falciparum EMBO J. 19 2000 2435 2443 (Pubitemid 30323533)
41. S. Duffy, and V.M. Avery Identification of inhibitors of Plasmodium falciparum gametocyte development Malar. J. 12 2013 408
42. C.J. Janse, B. Franke-Fayard, G.R. Mair, J. Ramesar, C. Thiel, S. Engelmann, K. Matuschewski, G.J. van Gemert, R.W. Sauerwein, and A.P. Waters High efficiency transfection of Plasmodium berghei facilitates novel selection procedures Mol. Biochem. Parasitol. 145 2006 60 70 (Pubitemid 41691855)
43. S. Yalaoui, S. Zougbédé, S. Charrin, O. Silvie, C. Arduise, K. Farhati, C. Boucheix, D. Mazier, E. Rubinstein, and P. Froissard Hepatocyte permissiveness to Plasmodium infection is conveyed by a short and structurally conserved region of the CD81 large extracellular domain PLoS Pathog. 4 2008 e1000010
44. O. Silvie, E. Rubinstein, J.-F. Franetich, M. Prenant, E. Belnoue, L. Rénia, L. Hannoun, W. Eling, S. Levy, C. Boucheix, and D. Mazier Hepatocyte CD81 is required for Plasmodium falciparum and Plasmodium yoelii sporozoite infectivity Nat. Med. 9 2003 93 96 (Pubitemid 36098266)